Spots Global Cancer Trial Database for lymphoplasmacytic lymphoma

Every month we try and update this database with for lymphoplasmacytic lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Treg Cells for AGVHD in Non-myeloablative UCB Transplant	NCT02118311	Hematologic Mal...	T Regulatory ce... Fludarabine Cyclophosphamid... Total Body Irra...	18 Years - 69 Years	Masonic Cancer Center, University of Minnesota
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies	NCT01474681	Acute Myelocyti... Acute Lymphocyt... Chronic Myeloge... Myelodysplastic... Chronic Lymphoc... Marginal Zone L... Follicular Lymp... Large-cell Lymp... Lymphoblastic L... Burkitt's Lymph... High Grade Lymp... Mantle-cell Lym... Lymphoplasmacyt...	HSC835	10 Years - 55 Years	Novartis
Study of VTD in Waldenstrom's Macroglobulinemia	NCT03335098	Waldenstrom Mac... Lymphoplasmacyt...	Bortezomib	19 Years -	Seoul National University Hospital
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL	NCT03019666	Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt...	Nicotinamide Ex...	18 Years - 70 Years	Masonic Cancer Center, University of Minnesota
Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL	NCT03019666	Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt...	Nicotinamide Ex...	18 Years - 70 Years	Masonic Cancer Center, University of Minnesota
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia	NCT00142129	Waldenstrom's M... Lymphoplasmacyt...	Bortezomib (Vel...	18 Years - 90 Years	Dana-Farber Cancer Institute
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT03410901	B-Cell Non-Hodg... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt...	Anti-OX40 Antib... Laboratory Biom... Radiation Thera... TLR9 Agonist SD...	18 Years -	Stanford University
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	NCT03314974	Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M...	HSCT with TBI R... HSCT with Non-T...	- 60 Years	Masonic Cancer Center, University of Minnesota
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT03410901	B-Cell Non-Hodg... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt...	Anti-OX40 Antib... Laboratory Biom... Radiation Thera... TLR9 Agonist SD...	18 Years -	Stanford University
Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas	NCT01282424	Follicular Lymp... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L...	Idelalisib	18 Years -	Gilead Sciences
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases	NCT02145039	Acute Leukemias Burkitt's Lymph... Chronic Myeloge...	Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ...	- 74 Years	Masonic Cancer Center, University of Minnesota
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas	NCT04883437	Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Indolent Non-Ho... Lymphoplasmacyt... Lymphoprolifera... Mantle Cell Lym... Marginal Zone L...	Acalabrutinib Obinutuzumab Quality-of-Life... Questionnaire A...	18 Years -	Emory University
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia	NCT00142129	Waldenstrom's M... Lymphoplasmacyt...	Bortezomib (Vel...	18 Years - 90 Years	Dana-Farber Cancer Institute
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma	NCT02339922	Chronic Lymphoc... Follicular Lymp... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Extra... Refractory Extr... Small Lymphocyt... Waldenstrom Mac...	Ixazomib Citrat... Laboratory Biom... Rituximab	18 Years -	University of Washington
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma	NCT04840602	Lymphoplasmacyt... Waldenstrom Mac...	Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Ibrutinib Positron Emissi... Rituximab Venetoclax	18 Years -	National Cancer Institute (NCI)
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders	NCT03601819	Lymphoma, T-Cel... Lymphoma, T-Cel... Chronic Lymphoc... Lymphoprolifera... Waldenstrom Mac... Lymphoplasmacyt... Mantle Cell Lym...	Pacritinib	18 Years -	University of Michigan Rogel Cancer Center
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia	NCT02952508	Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous...	Iopofosine I 13... Iopofosine I 13... Iopofosine I 13...	18 Years -	Cellectar Biosciences, Inc.
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies	NCT03329950	Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt...	CDX-1140 CDX-301 pembrolizumab Chemotherapy	18 Years -	Celldex Therapeutics
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL	NCT02142530	Non-Hodgkin Lym... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... Peripheral T-ce...	Carfilzomib Belinostat	18 Years -	Massachusetts General Hospital
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	NCT03314974	Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M...	HSCT with TBI R... HSCT with Non-T...	- 60 Years	Masonic Cancer Center, University of Minnesota
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma	NCT03010358	Anemia B-Cell Prolymph... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Hairy Cell Leuk... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... Richter Syndrom...	Entospletinib Laboratory Biom... Obinutuzumab Pharmacological...	18 Years -	OHSU Knight Cancer Institute
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies	NCT02991898	Acute Lymphobla... Burkitt Lymphom... Natural Killer ... Chronic Myeloge... Myelodysplastic... Large-cell Lymp... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Hodgkin Lymphom... Multiple Myelom... Acute Myelogeno... Biphenotypic Le... Undifferentiate...	Infusion of Tre...	18 Years - 75 Years	Masonic Cancer Center, University of Minnesota
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies	NCT01163201	Hematologic Mal... Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Anemia, Refract... Chronic Myelopr... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Large Cell Non-... Lymphoblastic L... Burkitt's Lymph... High Grade Non-...	Treg cells CD3+ Teff cells Fludarabine Cyclophosphamid... Total body irra... Umbilical cord ...	18 Years - 55 Years	Masonic Cancer Center, University of Minnesota
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas	NCT06340737	Follicular Lymp... Mantle Cell Lym... Hairy Cell Leuk... Lymphoplasmacyt... Burkitt Lymphom... Marginal Zone L... Waldenstrom Mac...	CD22CART Infusi...	18 Years -	Stanford University
Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia	NCT02952508	Waldenstrom Mac... Multiple Myelom... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Central Nervous...	Iopofosine I 13... Iopofosine I 13... Iopofosine I 13...	18 Years -	Cellectar Biosciences, Inc.
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma	NCT03884998	Chronic Lymphoc... Diffuse Large B... Follicular Lymp... Indolent Non-Ho... Lymphoplasmacyt... Marginal Zone L... Richter Syndrom...	Copanlisib Nivolumab	18 Years -	City of Hope Medical Center
Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma	NCT01209871	Lymphoplasmacyt...	Autologous Lymp... Laboratory Biom...	18 Years -	M.D. Anderson Cancer Center
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)	NCT00923507	Waldenstrom Mac... Lymphoplasmacyt... Monoclonal B-Ce... Small Lymphocyt... CLL (Chronic Ly...		18 Years - 110 Years	National Institutes of Health Clinical Center (CC)
T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies	NCT01163201	Hematologic Mal... Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Anemia, Refract... Chronic Myelopr... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Large Cell Non-... Lymphoblastic L... Burkitt's Lymph... High Grade Non-...	Treg cells CD3+ Teff cells Fludarabine Cyclophosphamid... Total body irra... Umbilical cord ...	18 Years - 55 Years	Masonic Cancer Center, University of Minnesota
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma	NCT00644189	Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Small Lymphocyt... Lymphoplasmacyt... Low Grade B-cel... Diffuse Large B... Peripheral T-ce... Angioimmunoblas... Anaplastic Larg...	Clofarabine	18 Years -	Massachusetts General Hospital
Immune Responses to COVID-19 Vaccination in Lymphoma Patients	NCT04858568	Classical Hodgk... Diffuse Large B... Primary Mediast... High-grade B-ce... Burkitt Lymphom... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Nodular Lymphoc... Peripheral T-ce...		18 Years -	University Hospital Southampton NHS Foundation Trust
Carfilzomib Plus Belinostat in Relapsed/Refractory NHL	NCT02142530	Non-Hodgkin Lym... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... Peripheral T-ce...	Carfilzomib Belinostat	18 Years -	Massachusetts General Hospital
Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma	NCT03884998	Chronic Lymphoc... Diffuse Large B... Follicular Lymp... Indolent Non-Ho... Lymphoplasmacyt... Marginal Zone L... Richter Syndrom...	Copanlisib Nivolumab	18 Years -	City of Hope Medical Center
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies	NCT03329950	Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt...	CDX-1140 CDX-301 pembrolizumab Chemotherapy	18 Years -	Celldex Therapeutics
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	NCT04545762	Refractory Non-... Burkitt Lymphom... Mantle Cell Lym... Follicular Lymp... Lymphoplasmacyt... Primary Mediast... Diffuse Large B... Small Lymphocyt... Transformed Lym...	Fludarabine Cyclophosphamid... anti-CD19 CAR-T...	18 Years -	University of California, San Francisco
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases	NCT02145039	Acute Leukemias Burkitt's Lymph... Chronic Myeloge...	Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ...	- 74 Years	Masonic Cancer Center, University of Minnesota
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.	NCT00801281	Follicular Lymp... Marginal Zone L... Small Lymphocyt... Lymphoplasmacyt...	Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone 1 Prednisone 2	18 Years -	Polish Lymphoma Research Group
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma	NCT02339922	Chronic Lymphoc... Follicular Lymp... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Extra... Refractory Extr... Small Lymphocyt... Waldenstrom Mac...	Ixazomib Citrat... Laboratory Biom... Rituximab	18 Years -	University of Washington
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia	NCT00142129	Waldenstrom's M... Lymphoplasmacyt...	Bortezomib (Vel...	18 Years - 90 Years	Dana-Farber Cancer Institute
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies	NCT04279405	Small Lymphocyt... Lymphoplasmacyt... Marginal Zone L... Mantle Cell Lym... Diffuse Large B...	YY-20394	18 Years -	Shanghai YingLi Pharmaceutical Co. Ltd.
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.	NCT00801281	Follicular Lymp... Marginal Zone L... Small Lymphocyt... Lymphoplasmacyt...	Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone 1 Prednisone 2	18 Years -	Polish Lymphoma Research Group
Study of VTD in Waldenstrom's Macroglobulinemia	NCT03335098	Waldenstrom Mac... Lymphoplasmacyt...	Bortezomib	19 Years -	Seoul National University Hospital
Treg Cells for AGVHD in Non-myeloablative UCB Transplant	NCT02118311	Hematologic Mal...	T Regulatory ce... Fludarabine Cyclophosphamid... Total Body Irra...	18 Years - 69 Years	Masonic Cancer Center, University of Minnesota
Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia	NCT00566332	Waldenström Mac... Lymphoplasmacyt... Splenic Margina...	Chlorambucil Fludarabine	18 Years -	French Study Group on Chronic Lymphoid Leukemia
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma	NCT00644189	Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Small Lymphocyt... Lymphoplasmacyt... Low Grade B-cel... Diffuse Large B... Peripheral T-ce... Angioimmunoblas... Anaplastic Larg...	Clofarabine	18 Years -	Massachusetts General Hospital
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia	NCT05281809	B-Cell Lymphoma B Acute Lymphob... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Lymphoplasmacyt... Chronic Lymphoc... Transformed Lym...	Chimeric Antige...	18 Years - 79 Years	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.	NCT00801281	Follicular Lymp... Marginal Zone L... Small Lymphocyt... Lymphoplasmacyt...	Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone 1 Prednisone 2	18 Years -	Polish Lymphoma Research Group
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas	NCT03410901	B-Cell Non-Hodg... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt...	Anti-OX40 Antib... Laboratory Biom... Radiation Thera... TLR9 Agonist SD...	18 Years -	Stanford University
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease	NCT00719888	Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Burkitt Lymphom... Chronic Lymphoc... Chronic Myeloge... Chronic Phase C... Follicular Lymp... Lymphoblastic L... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... Myelofibrosis Non-Hodgkin Lym... Plasma Cell Mye... Prolymphocytic ... Refractory Anem... Small Lymphocyt...	Cyclophosphamid... Cyclosporine Double-Unit Umb... Fludarabine Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ... Thiotepa	6 Months - 45 Years	Fred Hutchinson Cancer Center
Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma	NCT03010358	Anemia B-Cell Prolymph... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Hairy Cell Leuk... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... Richter Syndrom...	Entospletinib Laboratory Biom... Obinutuzumab Pharmacological...	18 Years -	OHSU Knight Cancer Institute
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases	NCT01962636	Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Plasma Cell Leu... Myelofibrosis Myelodysplasia Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large B... Lymphoblastic L... Burkitt's Lymph... Non-Hodgkin Lym... Multiple Myelom...	Fludarabine Cyclophosphamid... Total Body Irra... Cyclosporine A Mycophenylate m... Umbilical cord ...	- 55 Years	Masonic Cancer Center, University of Minnesota
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases	NCT01962636	Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Plasma Cell Leu... Myelofibrosis Myelodysplasia Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large B... Lymphoblastic L... Burkitt's Lymph... Non-Hodgkin Lym... Multiple Myelom...	Fludarabine Cyclophosphamid... Total Body Irra... Cyclosporine A Mycophenylate m... Umbilical cord ...	- 55 Years	Masonic Cancer Center, University of Minnesota
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases	NCT02145039	Acute Leukemias Burkitt's Lymph... Chronic Myeloge...	Fludarabine Cyclophosphamid... Total Body Irra... Haploidentical ...	- 74 Years	Masonic Cancer Center, University of Minnesota

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: